Comparison between a cognitive behavioural alcohol programme and post-mailed minimal intervention in high-risk drinking university freshmen: Results from a randomized controlled trial

被引:21
|
作者
Johnson, KO
Berglund, M
机构
[1] U MAS, Dept Clin Alcohol Res, S-20502 Malmo, Sweden
[2] Lund Univ, Malmo Univ Hosp, Dept Clin Alcohol Res, S-20502 Malmo, Sweden
来源
ALCOHOL AND ALCOHOLISM | 2006年 / 41卷 / 02期
关键词
D O I
10.1093/alcalc/agh243
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aim: Examine the effect of a 10 h intervention programme compared with post-mailed minimal intervention (PMMI) given to high-risk alcohol-drinking university freshmen in a random design. Method: In total 693 freshmen at the Lund Institute of Technology, Lund University, Sweden were included in the study. A cognitive behavioural alcohol program (CBAP) or PMMI was given to high-risk drinking freshmen (n = 177) in a randomized design. A 10-item screening instrument, Alcohol Use Disorder Identification Test (AUDIT), was used before and 1 year after the intervention programmes were given. Results: There were no significant differences between the CBAP and the PMMI groups. Both groups declined their AUDIT scores with -1.7 [CI 95% -2.6, -0.7] and -2.7 [CI 95% -3.6, -1.7], respectively which could be explained by effects of regression to the mean. Conclusion: No significant differences between the groups were found.
引用
收藏
页码:174 / 180
页数:7
相关论文
共 43 条
  • [31] Comparison of a theory-based (AIDS Risk Reduction Model) cognitive behavioral intervention versus enhanced counseling for abused ethnic minority adolescent women on infection with sexually transmitted infection: Results of a randomized controlled trial
    Champion, Jane Dimmitt
    Collins, Jennifer L.
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2012, 49 (02) : 138 - 150
  • [32] Comparison of Ultrathin- Versus Thin-Strut Stents in Patients With High Bleeding Risk PCI: Results From the COMPARE 60/80 HBR Trial: An Open-Label, Randomized, Controlled Trial
    Smits, Pieter C.
    Tonino, Pim A. L.
    Hofma, Sjoerd H.
    van Kuijk, Jan-Peter
    Spano, Fabrizio
    Al Mafragi, Amar
    Pisters, Ron
    Polad, Jawed
    Bogaerts, Kris
    Oemrawsingh, Rohit M.
    Paradies, Valeria
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (10)
  • [33] Comparison of fdg pet-ct with conventional imaging in the staging of high-risk renal cancers and transitional cell carcinoma of bladder (COPPER-T): A prospective randomized controlled trial - trial protocol and initial short-term analysis of results
    Jena, R.
    Tripathi, S.
    Taywade, S.
    Yadav, T.
    Bhargava, P.
    Choudhary, G. R.
    Sandhu, A. S.
    EUROPEAN UROLOGY, 2023, 83 : S752 - S752
  • [34] Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies (vol 48, pg 570, 2013)
    van den Brink, W.
    Aubin, H. -J
    Bladstroem, A.
    Torup, L.
    Gual, A.
    Mann, K.
    ALCOHOL AND ALCOHOLISM, 2013, 48 (06): : 746 - 746
  • [35] Weekly Cisplatin vs. Triweekly Docetaxel Plus Cisplatin With Concurrent Chemoradiation in Post-Operative Treatment for Cervical Cancer With High-Risk Pathological Factors: A Randomized Controlled Phase III Trial From a Single Institution
    Zhang, Y.
    Liu, C.
    Yang, H.
    Shi, M.
    Wei, L. C.
    Zhao, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S18 - S18
  • [36] Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017
    Schrappe, Martin
    Locatelli, Franco
    Valsecchi, Maria Grazia
    Cario, Gunnar
    Vossen-Gajcy, Michaela
    Stary, Jan
    Attarbaschi, Andishe
    Bodmer, Nicole
    Barbaric, Draga
    Elitzur, Sarah
    Silvestri, Daniela
    Kolenova, Alexandra
    Moericke, Anja
    Bourquin, Jean-Pierre
    Dalla-Pozza, Luciano
    Stanulla, Martin
    Izraeli, Shai
    Rizzari, Carmelo
    Poyer, Fiona
    von Stackelberg, Arend
    Conter, Valentino
    Zimmermann, Martin
    Biondi, Andrea
    BLOOD, 2023, 142
  • [37] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
    Pardanani, Animesh
    Tefferi, Ayalew
    Masszi, Tamas
    Mishchenko, Elena
    Drummond, Mark W.
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Jurgutis, Mindaugas
    Ribrag, Vincent
    Rambaldi, Alessandro
    Koh, Liang Piu
    Rose, Shelonitda
    Zhang, Jun
    Harrison, Claire
    BLOOD, 2020, 136
  • [38] Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities
    Vanzulli, Andrea
    Vigorito, Raffaella
    Buonomenna, Ciriaco
    Palmerini, Emanuela
    Quagliuolo, Vittorio
    Broto, Javier Martin
    Pousa, Antonio Lopez
    Grignani, Giovanni
    Brunello, Antonella
    Blay, Jean-Yves
    Diaz-Beveridge, Robert
    Ferraresi, Virginia
    Lugowska, Iwona A.
    Pizzamiglio, Sara
    Verderio, Paolo
    Duroni, Valeria
    Fontana, Valeria
    Morosi, Carlo
    Stacchiotti, Silvia
    Gronchi, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
    Ison, Michael G.
    Popejoy, Myra
    Evgeniev, Nikolay
    Tzekova, Maria
    Mahoney, Kathryn
    Betancourt, Natalia
    Li, Yong
    Gupta, Deepali
    Narayan, Kristin
    Hershberger, Ellie
    Connolly, Lynn E.
    Yalcin, Ilker
    Das, Anita F.
    Genge, John
    Smith, Michelle
    Campanaro, Ed
    Hawn, Pamela
    Schmidt, Pete
    Muniz, Heloisa Costa Ravagnani
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (06):
  • [40] Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/-1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
    Chavez, Marianna
    Miao, Jieling
    Pusztai, Lajos
    Goetz, Matthew P.
    Rastogi, Priya
    Ganz, Patricia A.
    Mamounas, Eleftherios
    Paik, Soonmyung
    Bandos, Hanna
    Razaq, Wajeeha
    O'Dea, Anne
    Kaklamani, Virginia
    Silber, Andrea L. M.
    Flaum, Lisa E.
    Andreopolu, Eleni
    Baar, Joseph
    Wendt, Albert G.
    Carney, Jennifer F.
    Sharma, Priyanka
    Gralow, Julie R.
    Lew, Danika L.
    Barlow, William E.
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2023, 83 (05)